JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Corvus Pharmaceuticals Inc

Cerrado

4.28 -0.7

Resumen

Variación precio

24h

Actual

Mínimo

4.18

Máximo

4.32

Métricas clave

By Trading Economics

Ingresos

27M

15M

Empleados

31

EBITDA

-1.8M

-9.9M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+201.62% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

82M

359M

Apertura anterior

4.98

Cierre anterior

4.28

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 ago 2025, 23:11 UTC

Ganancias

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 ago 2025, 22:45 UTC

Ganancias

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 ago 2025, 22:39 UTC

Ganancias

Great-West Lifeco Logs Lower 2Q Profit

5 ago 2025, 21:32 UTC

Ganancias

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 ago 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 ago 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 ago 2025, 23:19 UTC

Charlas de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 ago 2025, 23:03 UTC

Charlas de Mercado
Ganancias

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 ago 2025, 22:22 UTC

Ganancias

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 ago 2025, 22:21 UTC

Ganancias

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 ago 2025, 22:20 UTC

Ganancias

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 ago 2025, 22:18 UTC

Ganancias

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 ago 2025, 22:17 UTC

Ganancias

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 ago 2025, 22:17 UTC

Ganancias

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 ago 2025, 22:16 UTC

Ganancias

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 ago 2025, 22:16 UTC

Ganancias

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 ago 2025, 22:15 UTC

Ganancias

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 ago 2025, 22:13 UTC

Ganancias

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 ago 2025, 22:13 UTC

Ganancias

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 ago 2025, 22:12 UTC

Ganancias

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 ago 2025, 22:12 UTC

Ganancias

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 ago 2025, 21:58 UTC

Ganancias

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 21:30 UTC

Ganancias

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 ago 2025, 21:26 UTC

Ganancias

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 ago 2025, 21:23 UTC

Ganancias

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 ago 2025, 21:17 UTC

Ganancias

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparación entre iguales

Cambio de precio

Corvus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

201.62% repunte

Estimación a 12 Meses

Media 13 USD  201.62%

Máximo 17 USD

Mínimo 11 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.165 / 3.5827Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.